BioMarin Pharma (BMRN) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Why has the market become so unforgiving of AI earnings?
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.44 -1.83%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.04), $0.02 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $505.3 million versus the consensus estimate of $516.56 million.
GUIDANCE:
BioMarin Pharma sees 2022 revenue of $2.06-2.16 billion, versus the consensus of $2.12 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) Tops Q4 EPS by 11c, Beats on Revenue, Beats on iPhone sales, Misses China
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Inspire Medical Systems (INSP) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
